Alkermes Plc · NASDAQ:ALKS

Alkermes — Q1 2024 Earnings Presentation

13 slides from Alkermes's earnings presentation, May 1, 2024

  1. Slide 1: First Quarter 2021 Financial Results & Business Update

    First Quarter 2021 Financial Results & Business Update April 28, 2021 © 2021 Alkermes. All rights reserved.

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the co

  3. Slide 3: Agenda

    Agenda • Introduction Sandy Coombs, SVP, Corporate Affairs & Investor Relations • Corporate Update Richard Pops, Chief Executive Officer • Q1 2021 Financial Results Iain Brown, Chief Financial Officer • Q1 2021 Commercial Review Todd Nichols, Chief Commercial Officer • R&D Pipeline Update Richard Po

  4. Slide 4: Q1 2021 Financial Results Summary

    Q1 2021 Financial Results Summary Total Revenue GAAP Net Loss Non-GAAP Net Income $0 $20 $250 ($5) $18 $246.2 $251.4 $17.8 ($10) $16 $200 ($15) $14 $12 $150 ($20) ($22.4) $10 ($25) $8 $100 ($30) $6 ($35) $50 ($38.7) $4 ($40) $2 $1.7 $0 ($45) $0 Q1 2020 Q1 2021 Q1 2020 Q1 2021 Q1 2020 Q1 2021 In mill

  5. Slide 5: First Quarter 2021 Revenue Summary

    First Quarter 2021 Revenue Summary ∆ Q1’21 Q1’20 Q1’21 vs. In millions, except % Q1’20 VIVITROL® $74.5* $78.8 (5%)* ARISTADA®** $55.4 $51.0 9% Manufacturing & Royalty Revenue $119.8 $116.3 3% License Revenue $1.5 - N/A Research & Development Revenue $0.1 $0.2 N/A Total Revenue $251.4 $246.2 2% *Decr

  6. Slide 6: Alkermes: 2021 Financial Expectations

    Alkermes: 2021 Financial Expectations†* Financial Expectations for (in millions, except per share amounts) Expected net sales of Year Ending Dec. 31, 2021 proprietary products: Revenues $1,100 – $1,170 • VIVITROL® net sales of COGS $190 – $200 $315M – $345M R&D Expense $400 – $430 • ARISTADA® net sa

  7. Slide 7: Disciplined Capital Allocation Supports Highest ROI Priorities

    Disciplined Capital Allocation Supports Highest ROI Priorities Support profitable commercial portfolio Drive operating margins of commercial business and focus on profitability Prepare for anticipated launch of LYBALVI™ Advance nemvaleukin alfa Create value through innovation and position ALKS for f

  8. Slide 8: VIVITROL Performance and Expectations

    VIVITROL® Performance and Expectations • Q1’21 year-over-year net sales VIVITROL Quarterly Net Sales ($M) declined 5% to $74.5M, $100 driven by unit decline of 6% $90 − Gross-to-net deductions: $80 51.5% in Q1’21, compared to $70 50.6% in Q4’20, and an average of $60 49.9% in 2020 $50 − Inventory le

  9. Slide 9: ARISTADA Performance and Expectations

    ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales ($M)* • Q1’21 year-over-year net sales growth of 9% to $55.4M, $80 driven by unit growth of 6% $70 − Gross-to-net deductions: $60 53.3% in Q1’21, compared to 54.1% in Q4’20 $50 $40 − Inventory levels decreased by approximately $8.0M

  10. Slide 10: ARISTADA: Prescription Growth Trends

    ARISTADA®: Prescription Growth Trends • Q1 year-over-year growth of 11% on ARISTADA Quarterly TRx MOT TRx months of therapy (MOT) basis 60,000 − Outpaced overall atypical long- 50,000 acting injectable (LAI) market Q1 year-over-year growth of 3% 40,000 • Market share: − TRx MOT: 9.2% of atypical LAI

  11. Slide 11: Nemvaleukin Alfa Development Program Progress

    Nemvaleukin Alfa Development Program Progress Mucosal melanoma  Nemvaleukin granted Orphan Drug Designation by U.S. Food and Drug Administration  Initiated ARTISTRY-6 phase 2 monotherapy study of nemvaleukin Platinum-resistant ovarian cancer  Entered clinical trial collaboration and supply agreem

  12. Slide 12: Focus and Discipline Integral to R&D Portfolio Advancement

    Focus and Discipline Integral to R&D Portfolio Advancement Discovery Phase Preclinical Phase Phase 1 Phase 2 Phase 3 Nemvaleukin alfa Intravenous Dosing Nemvaleukin alfa Subcutaneous Dosing ALKS 1140 Neurology (Orphan) Orexin 2R Agonist HDAC Inhibitors Neurology/Neuropsychiatry (Non-Orphan) HDAC Inh

  13. Slide 13: www.alkermes.com

    www.alkermes.com © 2021 Alkermes. All rights reserved.

Alkermes — Q1 2024 Earnings Presentation on 6ix